TY  - BOOK
AU  - Elsayed Fekry Elsayed Omran,
AU  - Heba Aly El Sawah
AU  - Marwa Fouad Sharaf
AU  - Mahmoud Ahmed Ismail AbdElhameed 
TI  - Comparative Study Between Oral and Vaginal  Misoprostol for Induction of Labor in  Nulliparous Pregnant Women at or Beyond  Completed 41 Weeks
U1  - 618.1 
PY  - 2023///
KW  - Obstetrics and Gynecology
KW  - qrmak
KW  - Vaginal misoprostol
KW  - Oral misoprostol
KW  - Labor induction
N1  - Thesis (M.Sc.) -Cairo University, 2023.; Bibliography: pages 63-73.; Issued also as CD
N2  - Background: Although, vaginal application of misoprostol has been 
validated as a reasonable mean of induction, there is a patient resistance to 
digital examination and there is a risk of ascending infection. So, oral 
administration of misoprostol for labor induction was tried. 
Aim and objectives: To compare efficacy and safety of vaginal 
misoprostol with oral misoprostol for induction of labor in 
nulliparouspregnantwomenatorbeyondcompleted41weeks. 
Subjects and methods: Eighty nulliparous pregnant women who were 
candidate for labor induction at or beyond completed 41 weeks divided into 
two groups: (Group 1):40 pregnant women who received vaginal 
misoprostol in a dose of 25μg and repeated every 6 hours if no response 
was achieved with a maximum of 4 doses, (Group 2):40 pregnant women 
who received oral misoprostol in a dose of 25μg and repeated every 6 hours 
if no response was achieved with a maximum of 4 doses. 
Results: There was no statistically significant difference between oral& 
vaginal misoprostol regarding induction to active stage of labor, induction 
to delivery interval, cesarean deliveries, number of doses needed, maternal 
or neonatal complications. On the other hand, oxytocin augmentation was 
significantly lower in the vaginal group. 
Conclusion: 25 mg orally administered misoprostol is similarly effective 
& safe as 25 mg vaginal misoprostol to induce labor in nulliparous women 
with an unripe cervix at or beyond completed 41weeks.; كانت الحاجة لزيادة تحفيز المخاض باستخدام الأوكسيتوسين أعلى بشكل يعتد به في مجموعة الميزوبروستول الفموى بالمقارنة مع مجموعة الميزوبروستول المهبلى. إن تناول 25 ملغ من الميزوبروستول عن طريق الفم فعالة وآمنة بشكل مشابه مثل تناول 25 ملغ من الميزوبروستول عن طريق المهبل للحث على المخاض عند النساء اللاتي لم ينجبن من قبل وأتممن 41 أسبوعًا من الحمل. ومع ذلك، وُجد أن الحاجة إلى تحفيز المخاض باستخدام الأوكسيتوسين أعلى لدى النساء اللائي استخدمن الميزوبروستول الفموي
ER  -